Cargando…
Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
INTRODUCTION: Thyroid cancer is a rare disease with an incidence of around 37,000 cases per year. However, its incidence is rising faster than many other cancers and for men this disease ranks highest overall in the rate of increase (2.4% annual increase) in cancer deaths. As the number of radioacti...
Autores principales: | Deshpande, Hari A, Gettinger, Scott, Sosa, Julie Ann |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899774/ https://www.ncbi.nlm.nih.gov/pubmed/20694064 |
Ejemplares similares
-
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011) -
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011) -
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012) -
Current status of vandetanib (ZD6474) in the treatment of non-small
cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010) -
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)